The latest chemotherapy news from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in chemotherapy.

Olaparib Under Review by EMA for BRCA-mutated, HER2-negative Breast Cancer

A marketing authorization application for olaparib (Lynparza) for the treatment of women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting has been accepted by the European Medicines Agency.

Read full article (External website)

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Read full article (External website)

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Read full article (External website)

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or estrogen receptor

Read full article (External website)

Trastuzumab Regimen Extends PFS in Rare Endometrial Cancer

Adding trastuzumab to chemotherapy increased progression-free survival for patients with advanced HER2/neu-positive uterine serous carcinoma,

Read full article (External website)

EMA Recommends Extension of Therapeutic Indications for Fosaprepitant

It is indicated for prevention of nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adult and paediatric patients

Read full article (External website)

Priority Review Granted by FDA for Nivolumab Plus Ipilimumab Combo for MSI-H/dMMR CRC

There has been a supplemental biologics license application (sBLA) granted priority review by the FDA for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cases of metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Promise Seen With Frontline Pembrolizumab Plus Chemotherapy in Ovarian Cancer

The combination of first-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab (Keytruda), followed by pembrolizumab maintenance therapy, was safe and tolerable in patients with advanced ovarian cancer, according to preliminary data from a small clinical trial presented at the 2018 Society of Gynecologic Oncology Annual Meeting.

Read entire post (External website)

trial Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC

According to findings from the Phase 3 IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Read full article (External website)

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

1st-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Source

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

2018-03-29 10:54:57

According to topline findings from the Phase 3 IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.

Source

Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

2018-03-29 10:42:10

Based on findings from the Phase 3 ECHELON-1 trial, brentuximab vedotin (Adcetris) has been approved by the FDA for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.

Source

Trials Consider Role of Immunotherapy in Breast Cancer

Trials Consider Role of Immunotherapy in Breast Cancer

2018-03-29 10:16:32

Mixed results have occured in recent trials testing immuotherapy in patients with breast cancer. Checkpoint inhibitors have been used as monotherapy in a pair of trials, reporting lackluster overall response rates. When immunotherapy was paired with chemotherapy, on the other hand, it usually revealed better results, and gave signals that immunotherapies combined with targeted agents could work better than immunotherapy alone.

Source